Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
110 hedge funds and large institutions have $957M invested in Revance Therapeutics, Inc. in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 47 increasing their positions, 28 reducing their positions, and 24 closing their positions.
68% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 28
34% more call options, than puts
Call options by funds: $2.94M | Put options by funds: $2.19M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 120 → 110 (-10)
9% less capital invested
Capital invested by funds: $1.05B → $957M (-$96.8M)
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$43.1M |
| 2 |
BlackRock
New York
|
+$15.7M |
| 3 |
JP Morgan Chase
New York
|
+$6.85M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$5.14M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$19.1M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$15.6M |
| 3 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
-$15M |
| 4 |
Millennium Management
New York
|
-$12.3M |
| 5 |
Jennison Associates
New York
|
-$10.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCS
126
Levin Capital Strategies
New York
| – | -$277K | -9,000 | Closed |
|
127
William Blair & Company
Chicago,
Illinois
| – | -$254K | -8,250 | Closed |
|
128
Verition Fund Management
Greenwich,
Connecticut
| – | -$233K | -7,567 | Closed |
|
|
SKK
129
Shepherd Kaplan Krochuk
Boston,
Massachusetts
| – | -$222K | -7,196 | Closed |
|
130
Parallax Volatility Advisers
San Francisco,
California
| – | -$121K | -4,040 | Closed |
|
|
FPFS
131
First Personal Financial Services
Charlotte,
North Carolina
| – | -$21K | -672 | Closed |
|
|
NIT
132
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$18K | -600 | Closed |
|
|
PHK
133
Point72 Hong Kong
Hong Kong
| – | -$17K | -540 | Closed |
|
134
Group One Trading
Chicago,
Illinois
| – | -$361 | -12 | Closed |
|
RVNC Hedge Fund Activity: Q2 2018 in Review
110 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2018, worth a combined $957M — down 9.2% from $1.05B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of RVNC and 15 opened new positions — a net loss of 9 holders — while 28 trimmed existing stakes and 47 added.
The largest buyer was Capital World Investors, opening a new position worth an estimated $43.1M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $19.1M sold.
- 110 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2018, down from 120 in Q1 2018.
- Funds reported $957M of Revance Therapeutics, Inc. stock for Q2 2018, down 9.2% quarter-over-quarter.
- 15 funds opened new Revance Therapeutics, Inc. positions in Q2 2018 and 24 closed out, a net change of -9 holders.
- The largest Revance Therapeutics, Inc. buyer in Q2 2018 was Capital World Investors, an estimated $43.1M added.
- The largest Revance Therapeutics, Inc. seller in Q2 2018 was Perceptive Advisors, an estimated $19.1M sold.
Based on aggregated 13F filings for Q2 2018.